STAAR Surgical Reports Q3 2026 Results with Strong Adjusted Sales Growth and Profitability Turnaround
STAAR Surgical (STAA) reported third-quarter 2026 results characterized by a significant turnaround in profitability. While GAAP net sales decreased 12% to $83.4 million due to a high comparison base from deferred China sales in the prior year, adjusted net sales grew by 21%. The company achieved a GAAP net income of $5.6 million per diluted share, a substantial improvement over the previous year's adjusted net loss. Growth was driven by strong performance in China and EMEA markets, alongside an outperformance in the U.S. market where regional sales grew 14% despite a decline in total domestic laser vision correction procedures. Management highlighted expanded patient eligibility in both the U.S. and Brazil as key future drivers. Despite temporary manufacturing and freight costs impacting gross margins, the company maintains a strong cash position of $206.4 million with zero debt.
Tickers: $STAA
Topics: adjusted ebitda china market growth gross profit margin net sales regional performance